Article Details

AstraZeneca, Daiichi Enhertu delays disease progression in breast cancer, meets study goal

Retrieved on: 2022-08-15 09:10:03

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca, Daiichi Enhertu delays disease progression in breast cancer, meets study goal. View article details on hiswai:

Excerpt

AstraZeneca (AZN) and Daiichi Sankyo's (DSKYF) (DSNKY) Enhertu delayed disease progression, meeting the main goal of a phase 3 trial in patients ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up